What Is Enterococcus and What Infections Does It Cause?

Enterococcus is a group of bacteria that normally live in your gut without causing harm, but can become dangerous pathogens when they reach parts of the body where they don’t belong. The genus contains over fifty species, though two in particular cause the vast majority of human infections: Enterococcus faecalis and Enterococcus faecium. These organisms are among the leading causes of healthcare-associated infections worldwide, responsible for urinary tract infections, bloodstream infections, heart valve infections, and wound infections, with a growing reputation for resisting the antibiotics used to treat them.

A Gut Resident That Becomes an Opportunist

The name “Enterococcus” comes from the Greek word for intestine, and it fits. These bacteria were first isolated from human stool in the early 1900s, and they remain a normal part of the microbial community in your digestive tract.¹ They also show up in smaller numbers in the vagina and mouth.² In healthy people, enterococci participate in normal immune system functioning and coexist peacefully with hundreds of other bacterial species in the gut.

Problems begin when something disrupts that balance. Courses of broad-spectrum antibiotics can wipe out competing bacteria and allow enterococci to multiply unchecked. Surgery, catheters, intravenous lines, and immune-suppressing treatments all create opportunities for these bacteria to escape the gut and reach sterile sites like the bloodstream, urinary tract, or surgical wounds. This is why enterococcal infections are overwhelmingly hospital-acquired: the patients most at risk are those already sick enough to be hospitalized, receiving antibiotics, and connected to medical devices.³

The Two Species That Matter Most

E. faecalis and E. faecium account for the overwhelming majority of enterococcal infections in humans, but they tend to affect different patients in different ways. E. faecalis is the more common of the two and typically shows up in urinary tract infections and in patients with underlying heart or blood vessel problems. E. faecium, on the other hand, tends to strike sicker patients: those in intensive care, those with cancer, and those who have already been treated with powerful antibiotics like carbapenems or broad-spectrum penicillins.⁴

The distinction matters clinically because E. faecium infections tend to be harder to treat and deadlier. An older but striking study found that the mortality rate for E. faecium bloodstream infections was about 50%, compared with roughly 11% for E. faecalis, a gap driven largely by how debilitated the E. faecium patients already were and by the bug’s greater resistance to antibiotics.⁵ More recent population-level data confirms that E. faecium carries higher resistance rates to ampicillin, vancomycin, and other commonly used drugs, and a higher overall case fatality rate.⁶

Urinary Tract Infections

Urinary tract infections are one of the most frequent enterococcal infections, and they almost always involve a catheter. When a tube sits in the bladder for days or weeks, enterococci can climb the surface, establish colonies, and set up an infection that ranges from a mild bladder infection to a serious kidney infection or even a route into the bloodstream. The organisms’ ability to form biofilms on catheter material is a key part of the story: bacteria embedded in a biofilm are shielded from both the immune system and from antibiotics circulating in the blood.⁷ E. faecalis bloodstream infections, in particular, are closely linked to a urinary source and to patients with abnormal urinary tract anatomy or urological cancers.⁶

Endocarditis

Enterococcal endocarditis, an infection of the heart’s inner lining and valves, is the most feared complication these bacteria can cause. Enterococci account for up to roughly a fifth of all infective endocarditis cases, with E. faecalis responsible for most of them.⁸ The infection generally hits elderly and frail patients, and it carries a high mortality rate.⁹

What makes enterococcal endocarditis particularly dangerous is how the infection progresses. The bacteria bind to damaged or abnormal heart valve tissue and build up clumps of bacteria, immune cells, and clotting proteins called vegetations. These vegetations shield the bacteria from antibiotics and the immune system. Pieces can break off and travel through the bloodstream to the brain, lungs, kidneys, or coronary arteries. One case report documented a patient whose mitral valve vegetation sent a fragment into a coronary artery, triggering a heart attack in someone with no underlying heart disease.¹⁰ Treatment typically requires weeks of intravenous antibiotics, often a combination of two drugs, and sometimes valve replacement surgery.

Bloodstream Infections and Surgical Wounds

Enterococcal bloodstream infections most commonly arise as a secondary event: bacteria from an infected urinary tract, a surgical wound, or an abdominal source spill into the blood. Enterococci are frequently isolated from intra-abdominal infections, particularly after bowel surgery or when the gut wall is damaged by disease.¹¹ In surgical wound infections, Enterococcus species are among the most common bacteria found, and they are especially prevalent when a wound requires surgical revision, appearing in about 30% of superficial surgical site infections in one study.¹²

Once enterococci reach the bloodstream, outcomes depend heavily on the patient’s overall condition. ICU admission, low consciousness, the presence of catheters, and underlying conditions like chronic kidney disease and cancer all sharply increase the risk of death.¹³ These are not infections that typically strike otherwise healthy people.

Why Enterococci Are So Hard to Kill

Enterococci have a reputation for laughing off antibiotics, and they earn it in two ways. First, they come with built-in resistance to several drug classes. They are naturally resistant to most cephalosporins and have reduced susceptibility to penicillin-type drugs. They tolerate low levels of aminoglycosides. This intrinsic resistance means that antibiotics commonly used for other infections simply do not work well against enterococci from the start.⁹

Second, and more worrying, enterococci are remarkably good at picking up new resistance from other bacteria. They can acquire resistance genes through mobile genetic elements that jump between bacterial cells. The most clinically important example is vancomycin resistance. Vancomycin-resistant enterococci, usually shortened to VRE, emerged as a major problem in hospitals starting in the late twentieth century. Because vancomycin was long considered a last-resort drug for resistant infections, VRE created a treatment crisis. The situation has since escalated further: strains resistant to both daptomycin and linezolid, the two main antibiotics used when vancomycin fails, have now been documented.¹⁴ In surveillance data from the United States, daptomycin resistance remains relatively uncommon overall (around 5% of E. faecium isolates tested), and linezolid resistance is rarer still (under 1%), but the trend is headed in the wrong direction.¹⁵

An additional layer of concern is that enterococci can potentially pass their vancomycin resistance genes to other, more virulent bacteria. This possibility has long worried infectious disease specialists, and transfer to Staphylococcus aureus, another hospital pathogen, has been confirmed in rare clinical cases.

How Biofilms Help Enterococci Persist

The ability of enterococci, especially E. faecalis, to form biofilms on medical devices is a critical piece of why these infections are so stubborn. A biofilm is essentially a community of bacteria encased in a self-produced matrix that sticks to a surface, whether that surface is a urinary catheter, a central venous line, or a prosthetic heart valve. E. faecalis strains isolated from catheter-related bloodstream infections produce significantly more biofilm than strains from other types of infection, suggesting that the ability to build these structures is what allows certain strains to cause device-related disease.¹⁶ Once a biofilm is established, antibiotic concentrations needed to clear the bacteria can be hundreds of times higher than what would kill the same bacteria floating freely. This is a major reason why device removal is often necessary to cure the infection.

Spreading in Hospitals

Enterococcal infections are overwhelmingly healthcare-associated, and VRE in particular spreads through hospitals via contaminated hands, shared equipment, and environmental surfaces. Enterococci are exceptionally hardy: they survive on dry surfaces like bed rails, doorknobs, and medical equipment for days to weeks. When stressed by starvation conditions, E. faecalis ramps up stress-resistance proteins that help it tolerate heat, acid, UV light, and even bleach at low concentrations.¹⁷

The typical chain of events runs from colonized patients outward. Whole-genome sequencing studies show that VRE strains tend to appear in a patient’s gut first and then spread into the hospital room environment, not the other way around.¹⁸ A patient can carry VRE in the gut without any symptoms, shedding the bacteria into the environment for weeks or months. Active surveillance screening of high-risk patients is one of the main tools hospitals use to detect these silent carriers and prevent onward transmission.

When Gut Bacteria Escape

For enterococci to cause infection, they generally need to leave the intestine and reach another body site. Research in animal models has shown that this translocation is not random: it requires the enterococcal population in the gut to reach a threshold level. In one study, E. faecalis did not significantly move through the intestinal wall into deeper tissues until its numbers hit roughly ten million cells per gram of intestinal content in the small intestine and roughly one billion per gram in the colon.¹⁹ This helps explain why antibiotic disruption of the normal gut flora is such a powerful risk factor: when competing species are killed off, enterococci can bloom past this threshold and begin pushing through the gut lining into the bloodstream.

Diagnosing Enterococcal Infections

Most enterococcal infections are diagnosed through standard microbiological cultures. A blood sample, urine specimen, or wound swab is cultured in the lab, and if enterococci grow, the lab identifies the species and tests which antibiotics it responds to. The species identification step matters because treatment choices differ substantially between E. faecalis and E. faecium.

Speed is important, especially for bloodstream infections, and newer molecular tools can shorten turnaround time. One rapid test uses fluorescent probes that bind to the bacteria’s genetic material directly in a positive blood culture bottle, differentiating E. faecalis from other enterococcal species in under half an hour with near-perfect accuracy.²⁰ Faster identification means clinicians can adjust antibiotic therapy sooner, which has real consequences when every hour counts in a bloodstream infection.

Treatment Options and Their Limits

For E. faecalis infections that remain susceptible to ampicillin, treatment is relatively straightforward: ampicillin, sometimes combined with a second drug for serious infections like endocarditis. The real challenge comes with resistant strains, particularly VRE. The main options for VRE bloodstream infections are daptomycin, linezolid, and in some regions teicoplanin, with dose optimization guided by blood-level monitoring playing an important role in getting the best results.²¹ None of these options is ideal: daptomycin can cause muscle toxicity, linezolid can suppress bone marrow production of blood cells during prolonged courses, and resistance to both is slowly climbing.

For the rare strains that resist essentially everything, experimental approaches are under investigation. Bacteriophage therapy, which uses viruses that specifically infect and kill bacteria, has shown promise in individual patients. In one case, a one-year-old child with a life-threatening VRE abdominal infection following liver transplantation was treated with intravenous injections of two phages twice daily for 20 days, resulting in successful clearance of the infection.²² In another case involving recurrent VRE bloodstream infections, adding phage therapy to the patient’s antibiotic regimen was associated with months of clinical improvement and reduced intestinal VRE burden.²³ These remain individual compassionate-use cases, not standard therapy, but they point toward a potential option when nothing else works.

The Livestock and Food Connection

Enterococcal resistance is not just a hospital problem. A major contributor to VRE in the environment was the use of avoparcin, a vancomycin-like drug, as a growth promoter in farm animals across Europe and other regions for decades. The drug selected for vancomycin-resistant strains in livestock, and after avoparcin was banned, VRE prevalence in animals declined but did not disappear.²⁴

A systematic review and meta-analysis found a measurable link between VRE prevalence in livestock and VRE prevalence in the human population in the same region: for every one-percentage-point increase in livestock VRE, human VRE went up by about three-quarters of a percentage point. A weaker but still statistically significant link existed between VRE in food products and human VRE.²⁵ The United States never approved avoparcin for agricultural use, which may partly explain why the VRE problem in the U.S. has been more tightly centered on hospitals rather than the community. But the finding underscores that antibiotic use in agriculture has real downstream consequences for human medicine.

The Probiotic Paradox

Some enterococcal strains are sold as probiotics, which may seem surprising given everything above. Certain E. faecium and E. faecalis strains have been marketed in dietary supplements and food products, with studies suggesting benefits for digestive health, respiratory infections, and cholesterol levels. A review identified 23 probiotic products containing enterococci from 12 different companies, and concluded that consumption appeared beneficial for various conditions without documented adverse effects in the studied populations.²⁶

The catch is that the line between “probiotic” and “pathogen” in the Enterococcus genus is blurry. Whole-genome analysis of commercially available probiotic products has found that some enterococcal probiotic strains carry genes for antibiotic resistance, virulence factors, and toxic metabolites. In one troubling finding, an E. faecalis strain from a probiotic product clustered genetically with a known pathogenic strain rather than with well-characterized safe probiotic lineages.²⁷ The concern is not that probiotic enterococci are likely to cause infections in healthy people, but that these strains could transfer resistance genes to other bacteria in the gut, gradually expanding the pool of resistant organisms. Regulatory approaches vary worldwide: the European Food Safety Authority has been cautious about approving enterococci as safe for food use, while regulations elsewhere are more permissive.

Ancient Survivors in Modern Hospitals

One reason enterococci thrive in hospitals may be written deep in their evolutionary history. Genomic analysis tracing the ancestry of Enterococcus species suggests that the genus diversified around the time animals first moved onto land, hundreds of millions of years ago. Life in terrestrial environments, where drying out and food scarcity are constant threats, would have favored exactly the traits that make enterococci such successful hospital pathogens today: tolerance of desiccation, starvation, and harsh chemical exposure.²⁸

Even the specific hospital-adapted lineages of E. faecalis appear to be older than the modern hospital itself. Molecular dating of hospital-associated genetic clusters estimates that some date back to the mid-nineteenth century, well before antibiotics, ICUs, or the invasive devices that define modern healthcare existed.²⁹ The implication is humbling: we did not create these hospital pathogens with our antibiotics and technology. We created the perfect environment for organisms that were already pre-adapted to survive exactly the stresses we throw at them.

Who Is Most at Risk

Enterococcal infections are not a significant threat to healthy people living in the community. The typical person at risk is hospitalized, often in an ICU, and has several overlapping vulnerabilities. Risk factors that emerge repeatedly across studies include:

Invasive devices: Urinary catheters, central venous lines, and mechanical ventilators all provide physical routes for bacteria to enter sterile body sites.
Prior antibiotics: Broad-spectrum antibiotic courses, especially vancomycin itself, disrupt the normal gut flora and give enterococci room to overgrow. In children, each additional day of vancomycin use increased the odds of VRE bloodstream infection by about 25%.³⁰
Immune suppression: Organ transplant recipients on anti-rejection drugs, cancer patients receiving chemotherapy, and anyone on long-term corticosteroids face elevated risk.
Chronic illness: Chronic kidney disease, cancer, liver disease, and heart failure all appear as independent risk factors across different studies.

For the general public, the practical takeaway is that enterococcal infections are a reason to minimize unnecessary antibiotic use and unnecessary catheter days in the hospital, not something to worry about during everyday life. If you or a family member is hospitalized for a serious illness, ask the care team whether catheters and central lines are still needed each day. The sooner they come out, the lower the risk.